Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025)

Historic Receivables - Other for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $727000.0.

  • Inhibrx Biosciences' Receivables - Other changed N/A to $727000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $727000.0, marking a year-over-year change of. This contributed to the annual value of $41000.0 for FY2024, which is 9324.55% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Receivables - Other stood at $727000.0 for Q3 2025.
  • Over the past 5 years, Inhibrx Biosciences' Receivables - Other peaked at $952000.0 during Q2 2024, and registered a low of $41000.0 during Q4 2024.
  • Over the past 3 years, Inhibrx Biosciences' median Receivables - Other value was $727000.0 (recorded in 2025), while the average stood at $611400.0.
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 9324.55% in 2024, then tumbled by 2331.93% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Receivables - Other stood at $607000.0 in 2023, then tumbled by 93.25% to $41000.0 in 2024, then soared by 1673.17% to $727000.0 in 2025.
  • Its Receivables - Other was $727000.0 in Q3 2025, compared to $730000.0 in Q2 2025 and $41000.0 in Q4 2024.